CytomX Therapeutics Inc (NAS:CTMX)
$ 1.06 0.04 (3.92%) Market Cap: 82.95 Mil Enterprise Value: -24.04 Mil PE Ratio: 6.24 PB Ratio: 0 GF Score: 52/100

CytomX Therapeutics, Inc. - Special Call Transcript

Feb 26, 2019 / 01:00PM GMT
Release Date Price: $13.13 (-31.47%)
Sean A. McCarthy
CytomX Therapeutics, Inc. - Chairman, CEO & President

Well, good morning, everybody. I'm Sean McCarthy, President, CEO and Chairman of CytomX Therapeutics.

I would like to extend a very warm welcome to all of you here in New York, and to everyone listening to our webcast. The CytomX team and I are very pleased to be here at our inaugural Research and Development Day. Before we get going, just a reminder that during the course of this morning's presentations, the team and I will be making certain forward-looking statements. More information concerning CytomX and associated risks and uncertainties is available on our website, in our press releases and in our public filings with the U.S. SEC.

So our principal goal for today is to provide a comprehensive overview of our technology, our programs and our vision for our company. CytomX is an organization with high science in our blood and innovation is inherent in everything we do, whether conceiving of novel product candidates in the lab or implementing creative strategies in clinical operations. I'm personally proud and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot